Have a feature idea you'd love to see implemented?
Let us know!
KPTI Karyopharm Therapeutics Inc
Price (delayed)
$0.7776
Market cap
$97.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.79
Enterprise value
$218.54M
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related
Highlights
The EPS has grown by 40% YoY and by 4.8% from the previous quarter
The net income has grown by 37% YoY and by 2.7% from the previous quarter
The equity has plunged by 59% YoY and by 21% from the previous quarter
Karyopharm Therapeutics's quick ratio has decreased by 32% YoY and by 19% from the previous quarter
Key stats
What are the main financial stats of KPTI
Market
Valuations
Earnings
Shares outstanding
125.31M
Market cap
$97.44M
Enterprise value
$218.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.47
Revenue
$148.44M
EBIT
-$54.76M
EBITDA
-$54.42M
Free cash flow
-$120.46M
Per share
Balance sheet
Liquidity
EPS
-$0.79
Free cash flow per share
-$0.96
Book value per share
-$1.28
Revenue per share
$1.19
TBVPS
$1.52
Total assets
$189.48M
Total liabilities
$349.12M
Debt
$194.26M
Equity
-$159.65M
Working capital
$123.26M
Debt to equity
-1.22
Current ratio
3
Quick ratio
2.69
Net debt/EBITDA
-2.23
Margins
Efficiency
Dividend
EBITDA margin
-36.7%
Gross margin
95.8%
Net margin
-58.9%
Operating margin
-84.9%
Return on assets
-41.2%
Return on equity
N/A
Return on invested capital
-20%
Return on capital employed
-42.8%
Return on sales
-36.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KPTI stock price
How has the Karyopharm Therapeutics stock price performed over time
Intraday
0.34%
1 week
-7.13%
1 month
-8.99%
1 year
5.34%
YTD
-10.1%
QTD
-6.31%
Financial performance
How have Karyopharm Therapeutics's revenue and profit performed over time
Revenue
$148.44M
Gross profit
$142.28M
Operating income
-$125.97M
Net income
-$87.48M
Gross margin
95.8%
Net margin
-58.9%
KPTI's net margin is up by 39% YoY and by 4.5% from the previous quarter
The net income has grown by 37% YoY and by 2.7% from the previous quarter
KPTI's operating margin is up by 6% QoQ
KPTI's operating income is up by 3.8% QoQ
Growth
What is Karyopharm Therapeutics's growth rate over time
Valuation
What is Karyopharm Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.47
The EPS has grown by 40% YoY and by 4.8% from the previous quarter
The equity has plunged by 59% YoY and by 21% from the previous quarter
The P/S is 90% lower than the 5-year quarterly average of 6.3 and 19% lower than the last 4 quarters average of 0.8
Efficiency
How efficient is Karyopharm Therapeutics business performance
The ROS has soared by 54% YoY and by 14% from the previous quarter
Karyopharm Therapeutics's return on invested capital has increased by 41% YoY and by 5% QoQ
KPTI's ROA is up by 8% YoY but it is down by 6% QoQ
Dividends
What is KPTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KPTI.
Financial health
How did Karyopharm Therapeutics financials performed over time
KPTI's total assets is 46% smaller than its total liabilities
Karyopharm Therapeutics's quick ratio has decreased by 32% YoY and by 19% from the previous quarter
KPTI's total assets is down by 30% year-on-year and by 11% since the previous quarter
The equity has plunged by 59% YoY and by 21% from the previous quarter
KPTI's debt to equity is up by 31% year-on-year and by 18% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.